Free Trial
NASDAQ:DYN

Dyne Therapeutics Q4 2024 Earnings Report

Dyne Therapeutics logo
$7.83 -0.02 (-0.25%)
As of 04/16/2025 04:00 PM Eastern

Dyne Therapeutics EPS Results

Actual EPS
-$0.88
Consensus EPS
-$0.92
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Dyne Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dyne Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, February 27, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Dyne Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 1, 2025, with a conference call scheduled on Friday, May 2, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Remove Ads

Dyne Therapeutics Earnings Headlines

Dyne Therapeutics appoints Ranade as CBO, Batra as CSO
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
Dyne Therapeutics (DYN) Receives a Buy from Piper Sandler
See More Dyne Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dyne Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyne Therapeutics and other key companies, straight to your email.

About Dyne Therapeutics

Dyne Therapeutics (NASDAQ:DYN), a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

View Dyne Therapeutics Profile

More Earnings Resources from MarketBeat